As observed with CLDN1 and CLDN4 targeting antibodies, administration of CLDN6-2-DM1 combined with sorafenib treatment in a model of sorafenib resistant HCC caused significant growth inhibition of HCC tumors (52, 60). The gene discussed is CLDN4; the disease is hepatocellular carcinoma.